Vor Bio raises $150M in private placement; appoints two new directors

Vor Biopharma Inc.

Private placement of 13.9M shares at $10.81 for gross proceeds of ~$150M.
New/existing investors include RA Capital, Forbion, Frazier Life Sciences, Caligan, Logos, Venrock.
Proceeds to advance telitacicept Phase 3 trials for myasthenia gravis and Sjögren's disease.
Director Sarah Reed resigned; Andrew Levin (RA Capital) and Wouter Joustra (Forbion) appointed.
Levin and Joustra receive standard director fees and option grants of 3,000 shares each.

item 1.01 item 3.02 item 5.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.98

Vor Biopharma Inc. issued 13,876,032 shares of common stock to institutional and accredited healthcare specialist investors for $10.81 per share, gross proceeds approximately $150 million.

Security: common stock
Shares: 13,876,032 shares
Purchaser: institutional and accredited healthcare specialist investors
Consideration: $10.81 per share, gross proceeds approximately $150 million

Exact text from the filing

Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, announced today that it has entered into a securities purchase agreement to sell 13,876,032 shares of its common stock at a price of $10.81 per share to a select group of institutional and accredited healthcare specialist investors in a private placement.

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.98

Vor Biopharma Inc. entered into Securities Purchase Agreement with certain investors valued at 13,876,032 shares of common stock at $10.81 per share for gross proceeds of approximately $150.0 mil (effective 2025-12-15).

Action: entry
Agreement: equity purchase
Counterparty: certain investors
Value: 13,876,032 shares of common stock at $10.81 per share for gross proceeds of approximately $150.0 mil
Effective: 2025-12-15

Exact text from the filing

On December 15, 2025, Vor Biopharma Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain investors (the “Investors”) pursuant to which the Company, in a private placement, agreed to issue and sell to the Investors an aggregate of 13,876,032 shares (the “Shares”) of the Company’s common stock, at a price per Share of $10.81, for gross proceeds of approximately $150.0 million (the “Private Placement”).

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.97

Vor Biopharma Inc. entered into Registration Rights Agreement with certain investors valued at Company obligated to file S-3 registration statement within 45 days of closing and use best efforts (effective 2025-12-15).

Action: entry
Agreement: equity purchase
Counterparty: certain investors
Value: Company obligated to file S-3 registration statement within 45 days of closing and use best efforts
Effective: 2025-12-15

Exact text from the filing

In connection with the Private Placement, the Company also entered into a Registration Rights Agreement, dated December 15, 2025 (the “Registration Rights Agreement”), with the Investors.

View on SEC.gov

43 equity issuances filed in the last 30 days. Browse all equity issuances →

Vor Biopharma Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-324768

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.